TribLIVE

| USWorld


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Alzheimer's drug trials to take different approach

Daily Photo Galleries

By USA Today
Sunday, Oct. 7, 2012, 5:40 p.m.
 

Timing might be everything when it comes to treating Alzheimer's disease, according to research being presented on Monday at a meeting of the American Neurological Association in Boston.

There is no cure for the disease, which affects more than 5 million people in the country, and numbers are expected to triple by 2050.

Researchers will discuss findings on two large drug trials. Results announced last summer found that they failed to improve cognition or daily functioning compared with a placebo. The bapineuzumab and solanezumab therapies were done on patients with mild to moderate dementia. The drugs target beta amyloid, a protein in the brain believed to cause the disease.

“We think we've been starting trials too late in the progression of the disease,” said Laurie Ryan of the National Institute on Aging.

Scientists are discovering mechanisms of the disease and how it progresses. A large study in the New England Journal of Medicine found that brain changes begin as early as 25 years before the onset of symptoms.

“I'm worried that we're intervening too late and with too little” of the drugs, said Reisa Sperling of Brigham and Women's Hospital in Boston.

 

 
 


Show commenting policy

Most-Read Nation

  1. Nurse defies Maine quarantine in standoff over Ebola
  2. Few knew of cyber attack on White House computer network
  3. Terminally ill woman may delay planned Nov. 1 suicide
  4. Ferguson grand jury cleared in leaks about police shooting of black teenager
  5. Plane slams into pilot training center at Kansas airport, killing 4
  6. Botched probe of suspected arms dealer echoed Fast and Furious, watchdog finds
  7. Inmate freed in landmark case
  8. Hawaii’s National Guard sent to lava flow site
  9. Wash. shooting survivor has jaw surgery
  10. Museum saves part of bomber plant
  11. Democratic areas flush with transportation grants
Subscribe today! Click here for our subscription offers.